Chai Discovery develops AI models that reason about biological structure and function to generate new molecular designs from scratch and put those models into a software platform used by pharma teams. The company reports partnerships and deployments with major pharmaceutical firms, including Eli Lilly and Pfizer. Its model lineup includes Chai-2, released in 2025 as the first zero-shot generative platform for fully de novo antibody design to achieve double-digit experimental success rates, and Chai-3, which materially improves target success rates and binding affinity versus its predecessor. Founded in 2024 and based in San Francisco, Chai aims to bring engineering precision, speed and scale to pre-clinical discovery. The company recently raised $400M in a Series C at a $3.8B valuation to accelerate R&D, deployment and partnerships.

Total raised

$630M

Funding rounds

4

Latest round

Series C

Latest activity

Jul 2026